GenSight Biologics SA (G49N) Income Statement
GenSight Biologics SA Income Statement
Last quarter (Q2 2026), GenSight Biologics SA's total revenue was $-856.00K, a decrease of 149.54% from the same quarter last year. In Q2, GenSight Biologics SA's net income was $-10.27M. See GenSight Biologics SA’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 1.00K | $ 2.63M | $ 1.27M | $ 2.58M | $ 5.28M | |
| $ 1.00K | $ 2.63M | $ 3.00M | $ 2.58M | $ 5.28M | |
| $ 11.06M | $ 18.44M | $ 32.66M | $ 30.42M | $ 33.40M | |
| Depreciation and Amortization | $ 465.00K | $ 1.06M | $ 3.03M | $ 1.06M | $ 928.00K |
| $ -11.24M | $ -14.76M | $ -21.73M | $ -26.77M | $ -25.52M | |
| $ -11.71M | $ -15.81M | $ -29.70M | $ -27.84M | $ -28.13M | |
| $ -336.00K | $ 1.83M | $ 3.48M | $ 215.00K | $ -489.00K | |
| $ -12.04M | $ -13.98M | $ -26.22M | $ -27.62M | $ -28.61M | |
| $ -12.04M | $ -14.00M | $ -26.22M | $ -27.62M | $ -28.62M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.08 | $ -0.15 | $ -0.54 | $ -0.60 | $ -0.63 |
| Diluted EPS | $ -0.08 | $ -0.15 | $ -0.54 | $ -0.60 | $ -0.63 |
| Weighted Average Shares Outstanding | 148.30M | 95.76M | 48.32M | 46.33M | 45.15M |
| Weighted Average Shares Outstanding (Diluted) | 148.30M | 95.76M | 48.32M | 46.33M | 45.15M |
Currency in EUR